Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Recursion Pharmaceuticals will work with Bayer to develop new drugs for fibrotic diseases under a deal that brings the AI-driven biotech 30 million dollars…
Bayer has signed a research collaboration with U.S. biotech Recursion Pharmaceuticals to develop new treatments for fibrotic diseases, with payments…
Bayer is making a 1 billion dollar bet on Recursion Pharmaceuticals' AI/ML phenomics drug discovery platform to advance multiple fibrosis programs across lung,…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Bayer and Recursion entered a strategic collaboration leveraging Recursion's AI-driven phenomics drug discovery platform to develop new therapies for fibrosis (lung, kidney, heart). Recursion received $30M upfront from Bayer; Leaps by Bayer led a $50M Series D investment. Up to ten programs with $100M+ in milestones each plus royalties. Total potential value ~$1.1B+.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Recursion Pharmaceuticals, Inc. (this deal) | 2020 | $1.1B | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2020 deals · Bayer AG deals · Cardiovascular deals